Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Publications

Genetic Reasons to Walk the Extra Mile to Prevent Prostate Cancer.

Bratt O. and Lamb AD., (2018), Eur Urol

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.

Sathianathen NJ. et al, (2018), Cochrane Database Syst Rev, 10

Pathologist Assessment of Novel Histological Features in Prostate Cancer

Tupper PM. et al, (2018), JOURNAL OF PATHOLOGY, 246, S42 - S42

Prostatic capsular incision during radical prostatectomy has important oncological implications. A systematic review and meta-analysis.

Philippou Y. et al, (2018), BJU Int

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.

Yang L. et al, (2018), EBioMedicine, 31, 182 - 189

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer

Yang L. et al, (2018), EBIOMEDICINE, 31, 182 - 189

First Report of Prostate-specific Membrane Antigen-targeted Immunotherapy in Prostate Cancer: The Future is Bright.

Lamb AD. et al, (2018), Eur Urol, 73, 653 - 655

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists’ perspective

Tan JL. et al, (2017), Urological Science, 28, 190 - 196

Diagnostic Pathways for Screen-detected Prostate Cancer: The Plot Thickens.

Hamdy FC. et al, (2017), Eur Urol

Orient Expression: Solving the Mystery of Asian Prostate Cancer?

Lamb AD. et al, (2017), Eur Urol

Systematic Review of Studies Reporting Positive Surgical Margins After Bladder Neck Sparing Radical Prostatectomy.

Bellangino M. et al, (2017), Curr Urol Rep, 18

Reducing Mortality in the Ageing Patient: Treatment of the Primary Tumour Is Not Necessary.

Lamb AD. et al, (2017), Eur Urol Focus, 3, 328 - 329

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer

Sathianathen NJ. et al, (2017), Cochrane Database of Systematic Reviews, 2017

The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.

Sathianathen NJ. et al, (2017), Future Oncol, 13, 1801 - 1807

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.

Johnston TJ. et al, (2017), Eur Urol, 71, 381 - 388

Corrigendum to "Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study" [EBioMedicine 2 (9) (2015) 1133-1144].

Ross-Adams H. et al, (2017), EBioMedicine, 17

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.

Lane A. et al, (2016), BJU Int, 118, 869 - 879

Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre.

Gnanapragasam VJ. et al, (2016), BJU Int, 118, 779 - 784

Whole blood mRNA in prostate cancer reveals a four-gene androgen regulated panel.

Thomas BC. et al, (2016), Endocr Relat Cancer, 23, 797 - 812

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.

Shaw GL. et al, (2016), Eur Urol, 70, 214 - 218

Load More

Include forthcoming?